NCT04942548 is a NA clinical trial of Ketogenic Diet in Heart Failure, sponsored by National Jewish Health.

Who is sponsoring NCT04942548?

NCT04942548 is sponsored by National Jewish Health.

What drugs are being tested in NCT04942548?

Interventions in NCT04942548: Ketogenic Diet.

What condition does NCT04942548 study?

NCT04942548 studies Heart Failure.

Is NCT04942548 still recruiting?

NCT04942548 is currently completed. Last updated 3 April 2024.

Last reviewed 2024-04-03 · How we verify

NCT04942548

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reverse HFpEF: Ketogenic Reversal of Heart Failure With Preserved Ejection Fraction Study

Completed NA Last updated 3 April 2024

What this trial tests

NA trial testing Ketogenic Diet in Heart Failure in 16 participants. Completed in 24 July 2023.

Timeline

25 July 2019

Primary endpoint
24 July 2023

24 July 2023

Quick facts

Lead sponsor	National Jewish Health
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	25 July 2019
Primary completion	24 July 2023
Estimated completion	24 July 2023
Sites	2 locations across United States

Drugs / interventions tested

Ketogenic Diet — full drug profile →

Conditions studied

Heart Failure — all drugs for Heart Failure →

Sponsor

National Jewish Health — full company profile →

Who can join

Adults 21 to 80, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This protocol is a prospective pilot study utilizing the intervention of a medically supervised, registered nurse and registered diabetes educator coached low-carbohydrate, ketogenic diet to examine the impact it has as a treatment for heart failure with preserved ejection fraction.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Ketones and the Heart: Metabolic Principles and Therapeutic Implications.
Matsuura TR, Puchalska P, Crawford PA, Kelly DP. · · 2023 · cited 123× · PMID 36996176 · DOI 10.1161/circresaha.123.321872
Lifestyle interventions in cardiometabolic HFpEF: dietary and exercise modalities.
Vacca A, Wang R, Nambiar N, Capone F, et al · · 2025 · cited 17× · PMID 39283525 · DOI 10.1007/s10741-024-10439-1
Cardiac energy substrate utilization in heart failure with preserved ejection fraction: reconciling conflicting evidence on fatty acid and glucose metabolism.
Shehadeh LA, Robleto E, Lopaschuk GD. · · 2025 · cited 14× · PMID 40251758 · DOI 10.1152/ajpheart.00121.2025
Ketone bodies in right ventricular failure: A unique therapeutic opportunity.
Blake M, Puchalska P, Kazmirczak F, Blake J, et al · · 2023 · cited 12× · PMID 38058654 · DOI 10.1016/j.heliyon.2023.e22227
Nonpharmacological Strategies in Heart Failure with Preserved Ejection Fraction.
Bohmke NJ, Billingsley HE, Kirkman DL, Carbone S. · · 2022 · cited 8× · PMID 36210133 · DOI 10.1016/j.ccl.2022.06.003
Therapeutic Ketosis for Heart Failure: A State-of-the-Art Review.
Kodur N, Nguyen C, Tang WHW. · · 2025 · cited 5× · PMID 40043832 · DOI 10.1016/j.cardfail.2025.01.028

Verify or expand the search:

Other trials of Ketogenic Diet

Trials testing the same drug.

NCT07121894 — Ketogenic Intervention for Bipolar Depression · NA · recruiting
NCT06894004 — Mechanism of Ketogenic Diet-Induced Hypercholesterolemia · NA · recruiting
NCT06515912 — Ketogenic Diet in Healthy Adults With Differing BMI · NA · completed
NCT06503809 — Efficacy and Safety of a Ketogenic Diet in Type 1 Diabetes · NA · recruiting
NCT06325644 — Well-Formulated Ketogenic Diet Polycystic Kidney Disease · NA · recruiting

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other National Jewish Health trials

Trials by the same sponsor.

NCT06435520 — Enhancing Hypnotic Medication Discontinuation in Primary Care · Phase 4 · recruiting
NCT06262282 — Mycobacteriophage Treatment of Non-tuberculosis Mycobacteria · enrolling by invitation
NCT06155747 — Transmission and Acquisition of Nontuberculous Mycobacteria Outbreak Investigation (TrANsMIt) · recruiting
NCT04724278 — Measuring Omalizumab Responses Using Real-world Evidence (MORRE) Study · unknown
NCT05313087 — COVID-19 Vaccine Response in Chronic Respiratory Conditions · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04942548 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Jewish Health
Last refreshed: 3 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04942548.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing